Comparison of Prognostic Gene Profiles Using qRT-PCR in Paraffin Samples: A Retrospective Study in Patients with Early Breast Cancer
Autor: | Rosario Madero, Andrés Redondo, Angelo Gámez-Pozo, Belén San José Valiente, Marta Mendiola, Juan Ángel Fresno Vara, Álvaro Pinto Marín, Enrique Espinosa, Manuel González Barón, David Hardisson, Iker Sánchez-Navarro, Pilar Zamora |
---|---|
Rok vydání: | 2009 |
Předmět: |
Adult
Oncology medicine.medical_specialty lcsh:Medicine Breast Neoplasms Disease-Free Survival Breast cancer Recurrence Internal medicine Gene expression Humans Medicine In patient Genetics and Genomics/Genomics lcsh:Science Gene Aged Retrospective Studies Aged 80 and over Multidisciplinary Reverse Transcriptase Polymerase Chain Reaction business.industry Gene Expression Profiling lcsh:R Reproducibility of Results Genetics and Genomics/Gene Expression Retrospective cohort study Middle Aged Prognosis medicine.disease Gene expression profiling Real-time polymerase chain reaction Lymphatic Metastasis Oncology/Breast Cancer Hormonal therapy Female lcsh:Q business Research Article |
Zdroj: | PLoS ONE, Vol 4, Iss 6, p e5911 (2009) PLoS ONE |
ISSN: | 1932-6203 |
DOI: | 10.1371/journal.pone.0005911 |
Popis: | INTRODUCTION: Gene profiling may improve prognostic accuracy in patients with early breast cancer, but this technology is not widely available. We used commercial assays for qRT-PCR to assess the performance of the gene profiles included in the 70-Gene Signature, the Recurrence Score and the Two-Gene Ratio. METHODS: 153 patients with early breast cancer and a minimum follow-up of 5 years were included. All tumours were positive for hormonal receptors and 38% had positive lymph nodes; 64% of patients received adjuvant chemotherapy. RNA was extracted from formalin-fixed paraffin-embedded (FFPE) specimens using a specific kit. qRT-PCR amplifications were performed with TaqMan Gene Expression Assays products. We applied the three gene-expression-based models to our patient cohort to compare the predictions derived from these gene sets. RESULTS: After a median follow-up of 91 months, 22% of patients relapsed. The distant metastasis-free survival (DMFS) at 5 years was calculated for each profile. For the 70-Gene Signature, DMFS was 95% -good prognosis- versus 66% -poor prognosis. In the case of the Recurrence Score, DMFS was 98%, 81% and 69% for low, intermediate and high-risk groups, respectively. Finally, for the Two-Gene Ratio, DMFS was 86% versus 70%. The 70-Gene Signature and the Recurrence Score were highly informative in identifying patients with distant metastasis, even in multivariate analysis. CONCLUSION: Commercially available assays for qRT-PCR can be used to assess the prognostic utility of previously published gene expression profiles in FFPE material from patients with early breast cancer. Our results, with the use of a different platform and with different material, confirm the robustness of the 70-Gene Signature and represent an independent test for the Recurrence Score, using different primer/probe sets. |
Databáze: | OpenAIRE |
Externí odkaz: |